Table 3 Antitumour activity in evaluable patients
Dose of epertinib | Arm A | Arm B | Arm C | ||||||
|---|---|---|---|---|---|---|---|---|---|
Epertinib + T | Epertinib + T + V | Epertinib + T + C | |||||||
400mg | 600mg | 800mg | 200mg | 400mg | 200mg | 400mg | 600mg | Overall | |
N=5 | N=9 | N=7 | N=5 | N=2 | N=4 | N=9 | N=4 | N=45 | |
BOR | |||||||||
CR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PR | 0 | 6 (66.7%) | 1 (14.3%) | 0 | 2 (100%) | 0 | 5 (55.6%) | 2 (50.0%) | 16 (35.6%) |
SD ≥ 6 months | 2 (40.0%) | 0 | 1 (14.3%) | 4 (80.0%) | 0 | 1 (25.0%) | 0 | 1 (25.0%) | 9 (20.0%) |
CBR | 2 (40.0%) | 6 (66.7%) | 2 (28.6%) | 4 (80.0%) | 2 (100%) | 1 (25.0%) | 5 (55.6%) | 3 (75.0%) | 25 (55.6%) |
PD | 2 (40.0%) | 1 (11.1%) | 2 (28.6%) | 0 | 0 | 1 (25.0%) | 1 (11.1%) | 1 (25.0%) | 8 (17.8%) |